Growth and metastasis of 13762NF mammary adenocarcinoma.
Item
-
Title
-
Growth and metastasis of 13762NF mammary adenocarcinoma.
-
Identifier
-
AAI9119676
-
identifier
-
9119676
-
Creator
-
Sabzevari, Helen S.H.
-
Contributor
-
Adviser: Jeanne Szalay
-
Date
-
1991
-
Language
-
English
-
Publisher
-
City University of New York.
-
Subject
-
Health Sciences, Immunology | Biology, General | Biology, Animal Physiology
-
Abstract
-
Using the transplantable mammary adenocarcinoma 13762NF, the growth and metastasis of intraocular tumors was examined following subcutaneous (SC) or intracameral (IC) tumor implantation. IC implantation of tumor lead to death after 7-9 weeks. In addition to extensive pulmonary metastasis, animals had metastasis to the cervical lymph nodes, body wall, heart, kidney, and liver. Animals receiving iridial implants with removal (enucleation) of tumor filled eyes prior to spread to the orbit remained healthy and the development of overt metastatic disease was prevented up to 2 years. When healthy enucleated rats were necropsied 0 days to 26 weeks post enucleation, small nodules were seen in the lung. SC tumors metastasize predominantly to lung and lymph node. Excision of small primary SC tumors did not prevent animals from dying after 7-8 weeks with overt pulmonary metastasis.;Examination of enucleated rats 3 months post-enucleation demonstrated the presence of small nodules in the lung, heart, or cervical lymph node. Histological and immunocytochemical analysis demonstrated the presence of carcinoma in 3 of 4 sampled nodules. Cell suspensions from enucleated rat organs containing nodules were inoculated into sublethally irradiated rats and caused cachexia and death. Cachexia and death were not observed when cell suspensions from control rats were inoculated into sublethally irradiated rats. Examination of old enucleated rats 1-3 years after enucleation revealed the presence of viable transplatable metastatic adenocarcinoma in 23% of the animals.;The effect of treatment with a new therapeutic immunomodulator, Linomide (LS2616) was examined using the 13762NF tumor in rats that received SC or IC tumor implants or intravenous inoculation of tumor cells. Linomide was administered continuously in drinking water at a low dose (LD, 15 mg/kg) or high dose (HD, 60 mg/kg) beginning either one week before (pre-treatment) or 2 weeks after (post-treatment) tumor challenge. Posttreatment with Linomide in SC experiments resulted in a significant decrease in tumor size, partial or complete regression of tumors, and a low incidence of apparent cures. In rats with ocular tumors Linomide was shown to significantly reduce pulmonary as well as extrapulmonary metastasis. In an experimental metastasis assay, Linomide did not effect pulmonary metastasis. The specific effect of treatment with Linomide depended upon the time of initiation of treatment and route of administration of tumor. In conjunction with in vivo experiments, in vitro assays were performed in order to assess the effect of Linomide on NK and macrophage cytotoxicity and on lymphocyte proliferative responses in rats that received SC or IC implants or IV inoculation of tumor. Examination of the above mentioned group revealed that Linomide was capable of enhancing macrophage activity and lymphocyte proliferation and of partially restoring depressed NK activity.
-
Type
-
dissertation
-
Source
-
PQT Legacy CUNY.xlsx
-
degree
-
Ph.D.
